Our innovative preclinical solutions empower your drug development journey with cutting-edge analytics and insights from inception to preclinical stages.
We help you navigate complex trial phases efficiently with data-driven methods & strategies tailored to Phase I-III trials for accelerated drug development.
Maximize your market potential and optimize your commercial strategies with our advanced analytical methods, data science, and tailored commercialization solutions for data-driven commercial success.
Harness the power of real-world data and real-world evidence to gather insights and shape future drug development cycles for enhanced efficacy and regulatory compliance.
Craft optimal trial designs with our advanced analytical methods to enhance efficiency and increase the probability of success throughout your drug’s lifecycle.
Empower your trial delivery by transforming trial designs into actionable strategies with our data-driven approach to ensure seamless delivery and successful outcomes.
We offer tailored analytics solutions for your specialized or niche projects enabling you to optimize both efficiency and precision in drug development.
Experience the future of flexible strategic partnerships with Analytics on Demand, providing adaptive and innovative solutions that transcend traditional models to achieve unparalleled operational excellence.
Maximize efficiency and outcomes with our project-based services, delivering specialized expertise, end-to-end biometrics, and focused solutions for unique projects, ensuring timely completion and exceptional results.
Cytel's software platform enables precise trial design and simulation, utilizing adaptive and Bayesian tools to optimize protocols and accelerate drug development with confidence and efficiency.
Trial Implementation and Decision Support Software
Our unique software package streamlines trial implementation with intuitive solutions for protocol development, randomization, and patient management, optimizing operational efficiency and ensuring study success.
Discover comprehensive solutions for every stage of development — from data and regulatory strategies to Phase I-IV clinical trials, market access planning, and beyond.
Learn about our rich history, visionary leadership, and core values. Our mission and vision drive us to deliver excellence in drug development globally.
Join our innovative team at Cytel! Explore exciting career opportunities in data science and statistics, analytical methods, and regulatory strategy. Advance the future of human health with us.
Our innovative preclinical solutions empower your drug development journey with cutting-edge analytics and insights from inception to preclinical stages.
We help you navigate complex trial phases efficiently with data-driven methods & strategies tailored to Phase I-III trials for accelerated drug development.
Maximize your market potential and optimize your commercial strategies with our advanced analytical methods, data science, and tailored commercialization solutions for data-driven commercial success.
Harness the power of real-world data and real-world evidence to gather insights and shape future drug development cycles for enhanced efficacy and regulatory compliance.
Craft optimal trial designs with our advanced analytical methods to enhance efficiency and increase the probability of success throughout your drug’s lifecycle.
Empower your trial delivery by transforming trial designs into actionable strategies with our data-driven approach to ensure seamless delivery and successful outcomes.
We offer tailored analytics solutions for your specialized or niche projects enabling you to optimize both efficiency and precision in drug development.
Experience the future of flexible strategic partnerships with Analytics on Demand, providing adaptive and innovative solutions that transcend traditional models to achieve unparalleled operational excellence.
Maximize efficiency and outcomes with our project-based services, delivering specialized expertise, end-to-end biometrics, and focused solutions for unique projects, ensuring timely completion and exceptional results.
Cytel's software platform enables precise trial design and simulation, utilizing adaptive and Bayesian tools to optimize protocols and accelerate drug development with confidence and efficiency.
Our unique software package streamlines trial implementation with intuitive solutions for protocol development, randomization, and patient management, optimizing operational efficiency and ensuring study success.
Learn about our rich history, visionary leadership, and core values. Our mission and vision drive us to deliver excellence in drug development globally.
Join our innovative team at Cytel! Explore exciting career opportunities in data science and statistics, analytical methods, and regulatory strategy. Advance the future of human health with us.
Dive into our scientific peer-reviewed publications to explore cutting-edge research and insights from our experts in drug development, advanced analytics and biostatistics.
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR) (2022) pp. 35-48.
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children’s Oncology Group (2022).
Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development (2022).
Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial (2022).
Developing a Prediction Model for Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Model Building Approaches (2022).
Comparison of Mortality Risk With Different Surgeon and Hospital Operative Volumes Among Individuals Undergoing Pancreatectomy by Emulating Target Trials in US Medicare Beneficiaries (2022).
Assessment of the Cow’s Milk-related Symptom Score (CoMiSS) as a diagnostic tool for cow’s milk protein allergy: a prospective, multicentre study in China (MOSAIC study) (2022).
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial (2022).
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies (2022).
Systematic review and evidence gap assessment of the clinical, quality of life, and economic burden of alpha-thalassemia. Musallam KM, Viprakasit V, Lombard L, Gilroy K, Rane A, Vinals L, Tam C, Rizzo M, Coates TD. EJHaem. 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. P. Moreau, C. Hulin, A. Perrot, W. Hua et al., Lancet Oncology 2024
Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina. Rey-Ares L, Ta A, Freigofaite D, Warren S, Mac Mullen M, Carballo C, Huang L., Vaccine. 2024
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study. Costa Clemens SA, Jepson B, Bhorat QE, Ahmad A, Akhund T, Aley PK, Bansal H, Bibi S, Kelly EJ, Khan M, Lambe T, Lombaard JJ, Matthews S, Pipolo Milan E, Olsson U, Ramasamy MN, Moura de Oliveira Paiva MS, Seegobin S, Shoemaker K, Szylak A, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group., Lancet Microbe. 2024
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity. Stanley AM, Aksyuk AA, Wilkins D, Green JA, Lan D, Shoemaker K, Tieu HV, Sobieszczyk ME, Falsey AR, Kelly EJ., Front Immunol. 2024
2024
Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life. Hosman T, van Heesbeen R, Bastian AR, Hu W, Comeaux C, Ligtenberg N, van Montfort B, Callendret B, Heijnen E., Hum Vaccin Immunother. 2024
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Ta A, Kühne F, Laurenz M, von Eiff C, Warren S, Perdrizet., J. Infect Dis Ther. 202
A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results. Jiang Y, Wang Y, Xiong H, Li W, Luo R, Chen W, Yin F, Lü J, Liang J, Chen WJ, Lu X, Wang H, Tang J, Monine M, Makepeace C, Jin X, Foster R, Chin R, Berger Z., Adv Ther. 2024
Opportunity and accessibility: an environmental scan of publicly available data repositories to address disparities in healthcare decision-making. Vinals L, Radhakrishnan A, Sarri G., Int J Equity Health. 2024
Editorial: Novel methods and technologies for the evaluation of drug outcomes and policies. Adamson B, Makady A, Sarri G, Mohamed O, Babar Z, Dawoud DM., Front Pharmacol. 2024
Impact of patient support programmes among patients with severe asthma treated with biological therapies: a systematic literature review and indirect treatment comparison. Rabe APJ, Loke WJ, Kielar D, Morris T, Shih VH, Olinger L, Musat MG, Lan Z, Harricharan S, Fulton O, Majeed A, Heaney LG., BMJ Open Respir Res. 2024
Real-world experience with filgotinib for rheumatoid arthritis in Germany : A retrospective chart review. Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, De Leonardis F, Orzechowski HD, Gurrath M, Krüger K. Z, Rheumatol. 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. Dimopoulos M, Sonneveld P, Manier S, Lam A, Roccia T, Schecter JM, Cost P, Pacaud L, Poirier A, Tremblay G, Lan T, Valluri S, Kumar S., BMC Cancer. 2024
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States. Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B., Pharmacoeconomics. 2024
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, Kearney M., Future Oncol. 2024
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany. Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS., Int J Chron Obstruct Pulmon Dis. 2024
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data. Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Deiters B, Maywald U, Wilke T, Kearney M., J Med Econ. 2024
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Saraf A, Gurjar R, Kaviraj S, Kulkarni A, Kumar D, Kulkarni R, Virkar R, Krishnan J, Yadav A, Baranwal E, Singh A, Raghuwanshi A, Agarwal P, Savergave L, Singh S; GEMCOVAC-OM Study Investigators., Nat Med. 2024
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States. Arora P, Gupta A, Mackay E, Heeg B, Thorlund K., Value Health. 2024
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States. Farber HW, Germack HD, Croteau NS, Simeone JC, Tang F, Paoli CJ, Doad G, Panjabi S, De Marco T., Pulm Circ. 2024
Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany. Luna J, Picker N, Wilke T, Lutz M, Hess J, Mörtl B, Xiong Y, Götze TO., BMC Cancer. 2024
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer. Struebing A, McKibbon C, Ruan H, Mackay E, Dennis N, Velummailum R, He P, Tanaka Y, Xiong Y, Springford A, Rosenlund M., J Comp Eff Res. 2024
Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes. Paoli CJ, Linder J, Gurjar K, Thakur D, Wyckmans J, Grieve S., J Health Econ Outcomes Res. 2024
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. Raad A, Rizzo M, Appiah K, Kearns I, Hernandez L., Pharmacoeconomics. 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn’s disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. D’Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S., Eur J Gastroenterol Hepatol. 2024
Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data. Schuster AK, Leisle L, Picker N, Bubendorfer-Vorwerk H, Lewis P, Hahn P, Wasem J, Finger RP., Ophthalmol Ther. 2024
Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis. Pacis S, Bolzani A, Heuck A, Gossens K, Kruse M, Fritz B, Maywald U, Wilke T, Kunz C., Oncol Ther. 2024
A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke. Kasner SE, Sondergaard L, Nakum M, Gomez Montero M, Hashim M, Landaas EJ., J Med Econ. 2024
Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W., Arthritis Res Ther. 2024
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis. Amonkar MM, Abderhalden LA, Fox GE, Frederickson AM, Grira T, Gozman A, Malhotra U, Malbecq W, Akers KG., Future Oncol. 2024
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Hlavacek P., Leuk Lymphoma. 2024
Value-based pricing: a potential solution to difficult pricing discussions and payers’ negotiations. Tremblay G, Poirier A, Monfort L., J Med Econ. 2024
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM., J Am Coll Cardiol. 2024
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Sarri G, Rizzo M, Upadhyaya S, Paly VF, Hernandez L., J Comp Eff Res. 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A., Br J Dermatol. 2024
Quantitative bias analysis for external control arms using real-world data in clinical in trials: a primer for clinical researchers. Thorlund K, Duffield S, Popat S, Ramagopalan S, Gupta A, Hsu G, Arora P, Subbiah V., J Comp Eff Res. 2024
Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Appiah K, Rizzo M, Sarri G, Hernandez L., J Comp Eff Res. 2024
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain. Lehne M, Kortüm KM, Ramasamy K, Zamagni E, d’Estrubé T, Zhuleku E, Hanna M, Shukla S, Ghiani M, Maywald U, Wilke T, Kellermann L, Perera S., Eur J Haematol. 2024
Claims-based algorithm to estimate the Expanded Disability Status Scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records. Muros-Le Rouzic E, Ghiani M, Zhuleku E, Dillenseger A, Maywald U, Wilke T, Ziemssen T, Craveiro L., Front Neurol. 2023
Improved estimation of overall survival and progression-free survival for state transition modeling. Wigfield PC, Heeg B, Ouwens M., J Comp Eff Res. 2024
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Hlavacek P., Curr Med Res Opin. 2024
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators., Lancet. 2024
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. Rudwaleit M, Mørup MF, Humphries B, Zannat NE, Willems D, Taieb V, Boonen A., RMD Open. 2023
Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis. Picker N, Hagiwara M, Baumann S, Marins EG, Wilke T, Ren K, Maywald U, Karki C, Strnad P., World J Hepatol. 2023
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases. Griesinger F, Ramagopalan S, Cheung WY, Wilke T, Mueller S, Gupta A, O’Sullivan DE, Arora P, Brenner DR, Froelich C, Inskip J, Maywald U, Subbiah V., Cancer. 2024
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ., BMJ. 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J., BMJ. 2023
Author Correction: Early-childhood linear growth faltering in low- and middle-income countries. Benjamin-Chung J, Mertens A, Colford JM Jr, Hubbard AE, van der Laan MJ, Coyle J, Sofrygin O, Cai W, Nguyen A, Pokpongkiat NN, Djajadi S, Seth A, Jilek W, Jung E, Chung EO, Rosete S, Hejazi N, Malenica I, Li H, Hafen R, Subramoney V, Häggström J, Norman T, Brown KH, Christian P, Arnold BF; Ki Child Growth Consortium., Nature. 2023
Global Burden of Asthma, and Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic Asthma. Rabe APJ, Loke WJ, Gurjar K, Brackley A, Lucero-Prisno Iii DE., J Asthma Allergy. 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland. Ramasamy MN, Kelly EJ, Seegobin S, Dargan PI, Payne R, Libri V, Adam M, Aley PK, Martinez-Alier N, Church A, Jepson B, Khan M, Matthews S, Townsend GT, Vekemans J, Bibi S, Swanson PA 2nd, Lambe T, Pangalos MN, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group., Lancet Microbe. 2023
Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer. von Eyben R, Hoffmann MA, Soydal C, Virgolini I, Tuncel M, Gauthé M, Kapp DS, von Eyben FE., Biomedicines. 2023
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis. Lopena OJ, Alphs LD, Sajatovic M, Turkoz I, Sun L, Johnston KL, Sliwa JK, Najarian DM, Starr HL., J Clin Psychiatry. 2023
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. van Hylckama Vlieg MAM, Nasserinejad K, Visser C, Bramer WM, Ashrani AA, Bosson JL, Crusan DJ, D’Alessio A, Fluharty ME, Ģībietis V, Hansson PO, Hara N, Jara-Palomares L, Kraaijpoel N, Mahé I, Marshall A, Ogino Y, Otero R, Versmissen J, Klok FA, Kruip MJHA, van der Rijt CCD, Geijteman ECT., EClinicalMedicine. 2023
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden. Sigurdardottir V, Engstrom A, Berling P, Olofsson T, Oldsberg L, Sadler S, Parra-Padilla D, Melis L, Willems D., J Med Econ. 2023
Causes and consequences of child growth faltering in low-resource settings. Mertens A, Benjamin-Chung J, Colford JM Jr, Coyle J, van der Laan MJ, Hubbard AE, Rosete S, Malenica I, Hejazi N, Sofrygin O, Cai W, Li H, Nguyen A, Pokpongkiat NN, Djajadi S, Seth A, Jung E, Chung EO, Jilek W, Subramoney V, Hafen R, Häggström J, Norman T, Brown KH, Christian P, Arnold BF; Ki Child Growth Consortium., Nature. 2023
Child wasting and concurrent stunting in low- and middle-income countries. Mertens A, Benjamin-Chung J, Colford JM Jr, Hubbard AE, van der Laan MJ, Coyle J, Sofrygin O, Cai W, Jilek W, Rosete S, Nguyen A, Pokpongkiat NN, Djajadi S, Seth A, Jung E, Chung EO, Malenica I, Hejazi N, Li H, Hafen R, Subramoney V, Häggström J, Norman T, Christian P, Brown KH, Arnold BF; Ki Child Growth Consortium., Nature. 2023
Economic burden of in-hospital AKI: a one-year analysis of the nationwide French hospital discharge database Monard C, Rimmelé T, Blanc E, Goguillot M, Benard S, Textoris J BMC Nephrol 24, 343
Incidence of Nd:YAG laser capsulotomy following cataract surgery: a population-based nation-wide study – FreYAG1 study Brezin A, Labbe A, Schweitzer C, Lignereux F, Rozot P, Goguillot M, Bugnard F, Dot C BMC Ophthalmol 23, 417 (2023)
Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System Gaujoux-Viala C, Bergmann JF, Goguillot M, Melaine A, Guerin M, Edouard A, Bénard S, Fautrel B RMD Open 2023
Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires Beillat M, Durand Zaleski I, Pirenne F, Chillotti L, Bénard S, Galacteros F Front Public Health. 2023
Severity and burden of sickle cell disease in France: a nationwide realworld study Brousse V, Bernaudin F, Melaine A, Goguillot M, Gallagher M, Benard S, Habibi A Haematologica. 2023 Mar 16
Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study Roupret M, Brouquet A, Colrat F, Diez-Andreu P, Prudent A, Chartier M, Gaudin AF, Bugnard F, Chillotti L, Bénard S, Branchoux S, Bellera C, Negrier S World Journal of Urology 2023
APIDIA 2017: an update of diabetes epidemiology in France Reznik Y, Naiditsch N, Thébault JF, Havet A, Bénard S, Riveline JP Médecine des Maladies Métaboliques – Volume 16, Issue 7, November 2022
Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France Roche N, Garcia G, de Larrard A, Cancalon C, Bénard S, Perez V, Mahieu A, Vieu L, Demoly P BMJ Open 2022
Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data Korobelnik JF, Delcourt C, Creuzot-Garcher C, Melaine A, Chassetuillier J, Lejeune A, Bénard S, Dupont-Benjamin L J Med Econ 2021
Cost-Utility of Acromegaly Pharmacological Treatments in a French Context de Rycke Y, Tubach F, Lafourcade A, Guillo S, Dalichampt M, Dahlab A, Bresse X, Uhart M, Bergeron C, Borne H, Cancalon C, Lajoinie A, Benard S Plos One 2020
Identifying chronic thromboembolic pulmonary hypertension through the French national hospital discharge database Cottin V, Avot D, Lévy-Bachelot L, Baxter C, Ramey DR, Catella L, Bénard S, Sitbon O, Teal S Plos One 2019
Epidemiological and economic burden of potentially HPV-related cancers in France Abramowitz L, Lacau Saint Guily J, Moyal-Barracco M, Bergeron C, Borne H, Dahlab A, Bresse X, Uhart M, Cancalon C, Catella L, Bénard S Plos One 2018
Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, Bénard S PLOS One 2017
Outcomes, risk factors and health burden of contrast-induced acute kidney injury: an observational study of one million hospitalizations with image-guided cardiovascular procedures Aubry P, Brillet G, Catella L, Schmidt A, Bénard S BMC Neprhol 2016
Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans Bénard S, Wright C, Voisine J, Olivier CW, Gaudelus J J Infect Public Health 2016
Hospital Cost of Staphylococcal Infection after Cardiothoracic or Orthopedic Operations in France: A Retrospective Database Analysis Schmidt A, Bénard S, Cyr S Surg Infect 2015
Acute Ischemic Stroke (AIS) Patient Management in French Stroke Units and Impact Estimation of Thrombolysis on Care Pathways and Associated Costs Schmidt A, Heroumb C, Caumettec D, Le Lay K, Bénard S Cerebrovascular Diseases 2015
Parcours de soins des patients atteints de cancer bronchique traités chirurgicalementHospital undertaking of patients with a resection of lung cancer Rivera C, Cancalon C, Schmidt A, Mazieres J, Falcozd PE, Dahan M, Benard S Revue des Maladies Respiratoires 2013
Fuites aériennes prolongées après résection pulmonaire : une étude descriptive nationale Rivera C, Bernard A, Falcoz PE, Thomas P, Schmidt A, Bénard S, Vicaut E, Tiffet O, Filaire M, Dahan M Chirurgie Thoracique Cardio-Vascualire 2011
Fuite aérienne prolongée après résection pulmonaire en France : fréquence et construction d’un score prédictif Schmidt A, Bénard S, Falcoz PE, Vicaut E, Rivera C, Dahan M Poster presented at EPI-CLIN (Conférence Francophone d’Epidémiologie Clinique), Marseille, May 2011
Characterization and prediction of prolonged air leak after pulmonary resection: a nationwide study setting up the index of prolonged air leak Rivera C, Bernard A, Falcoz PE, Thomas P, Schmidt A, Bénard S, Vicaut E, Dahan M Ann Thorac Surg 2011
Cost-minimization analysis of XELOX vs. FOLFOX-6 as first-line treatment of metastatic colorectal cancer in France Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Dominguez S, Florentin V, Douillard JY Oncology 2010
Evaluation of a Hospital-Home Medical Program (HHMP) for the management of chemotherapy-related toxicities in the outpatient setting Coriat R, Martin I, Forgeot d’Arc P, Mir O, Ropert S, Durand JP, Alexandre J, Koba S, Goldwasser F Poster presented at the European Society of Medical Oncology (ESMO) congress, Milan, October 2010
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Llédo G, Adenis A, Faroux R, Rebischung C, Kockler L, Douillard JY Br J Cancer 2010
Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium Dhont P, Trichard M, Largeron N, Rafia R, Bénard S J Med Econ 2008
Cost of screening and treatment of cervical dyskaryosis in Germany Petry KU, Breugelmans JG, Bénard S, Lamure E, Littlewood KJ, Hillemanns P Eur J Gynaecol Oncol 2008
Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland Szucs T, Largeron N, Dedes KJ, Rafia R, Bénard S Curr Med Res Opin 2008
2008
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis Kulasingam, S, Bénard S, Barnabas RV, Largeron N, Myers E Cost Eff Resour Alloc 2008
Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq® in France Huet F, Largeron N, Trichard M, Miadi-Fargier H, Jasso-Mosquedac G Vaccine 2007
Coût de la prise en charge du cancer invasif du col de l’utérus en France Arveux P, Bénard S ,Bouée S, Lafuma A, Martin L, Cravello L, Remy V, Breugelmans JG Bull Cancer 2007
Incidence, prise en charge et coût des condylomes acuminés anogénitaux chez les femmes consultant leur gynécologue en France Monsonego J, Breugelmans JG, Bouée S, Lafuma A, Bénard S, Remy V Gynecol Obstet Fertil 2007
Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK Brown RE, Breugelmans JG, Theodoratou D, Bénard S Curr Med Res Opin 2006
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps, Joshua S. Jacobs, Joseph K. Han, Jason K. Lee, Tanya M. Laidlaw, Nicole L. Martin, Scott Caveney, Christopher S. Ambrose, Neil Martin, Joseph D. Spahn & Flavia C. L. Hoyte, Advances in Therapy 2025
Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Khashayar Azimpour, Patricia Dorling, Irene Koulinska, Swati Kunduri, Zhiyi Lan, Julia Poritz, Gabriel Tremblay & Angie Raad-Faherty. Advances in Therapy 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. The New England Journal of Medicine. 2025
2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study. Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Neurology and Therapy. 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB; INTERLINK-1 investigators. Clinical Cancer Research. 2025
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas. Heeg B, Lee D, Adam J, Postma M, Ouwens M. Pharmacoeconomics. 2025
Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany. Roque H, Dun AR, Cooper A, Kienzle S, Welby S, Wilke T, Song J, Abé C. Advances in Therapy. 2025
Further Practical Guidance on Adjusting Time-To-Event Outcomes for Treatment Switching. Watkins C, Kleine E, Miranda M, Bourmaud E, Doehring O. Pharmaceutical Statistics. 2025
Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study. Bailey MD, Farge G, Mohanty S, Breau-Brunel M, Roy G, de Pouvourville G, de Wazieres B, Janssen C, Tauty S, Bugnard F, Goguillot M, Bénard S, Johnson KD. Human Vaccines and Immunotherapeutics. 2025
Epidemiology, treatment patterns, and associated risk factors in perianal fistulizing Crohn’s disease: A systematic literature review. McKay C, Bolzani A, Kienzle S, Geransar P, Panés J. World Journal of Gastrointestinal Surgery. 2025
Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments. van Beekhuizen S, Che M, Monfort L, Hashim M, Azough A, Kubitz N, Griffin A, Price M. Pharmacoecon Open. 2025
Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study. Batyrbekova N, Hultcrantz M, Ravn Landtblom A, Szulkin R, Dickman PW, Andersson TM, Syriopoulou E. British Journal of Haematology. 2025
Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces temperature-evoked pain in patients with peripheral neuropathic pain with sensory hypersensitivity, a randomized, double-blind, placebo-controlled, crossover study. Miclescu A, Karlsten R, Lönnstedt I, Halldin MM, Segerdahl M. Scandinavian Journal of Pain. 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Therapeutic Advances in Neurological Disorders. 2025
Evaluating the impact of population-based and cohort-based models in cost-effectiveness analysis: a case study of pneumococcal conjugate vaccines in infants in Germany. Perdrizet J, Schröder D, Kühne F, Schiffner-Rohe J, Laurenz M, Theilacker C, Ilic A, Ta A, von Eiff C. Journal of Medical Economics. 2025
Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn’s Perianal Fistulas: A Systematic Literature Review. White I, Karki C, Geransar P, Leisle L, Junker S, Fleshner P. Inflammatory Bowel Diseases. 2025
Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B. Advances in Therapy. 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study. Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C. Lung Cancer. 2025
Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Zamulko O, Karivedu V, Riaz MK, Monroe I, Romano A, Mulanda R, Kurtzweil N, Forsythe A, Allen CL, Harun N, Pan J, Rai S, El-Gamal D, Wise-Draper TM. Cancer Research Communications. 2025
Effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on maternal gestational weight gain in low-income and middle-income countries: a systematic review and individual participant data meta-analysis of randomised clinical trials. Liu E, Partap U, Shinde S, Wang D, Costa JC, Cliffer IR, Wang M, Nookala SK, Subramoney V, Briggs B, Hamer DH, Akurut H, Argaw A, Ashorn U, Chinkhumba J, Desai M, Divala TH, Elliott AM, Gutman JR, Hien A, Huybregts L, Kajubi R, Kakuru A, Kariuki S, Lachat C, Laufer MK, Luntamo M, Maleta K, Mathanga DP, Ochieng T, Ome-Kaius M, Patson N, Roberfroid D, Rogerson SJ, Toe LC, Unger HW, Webb EL, Fawzi WW. EClinicalMedicine. 2025
Treatment Effect Estimation With Potential Outcomes for a Single-Arm Trial Compared With Historical Controls: A Case Study of Locally Recurrent Head and Neck Squamous Cell Carcinoma Patients Treated With Adjuvant Nivolumab. Harun N, Sparapani R, Laud PW, Sivaganesan S, Leddon JL, Haque S, Tang AL, Wise-Draper TM. Head Neck. 2025
Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population. García FÁ, Martinón-Torres F, Pineda V, López-Ibáñez de Aldecoa A, Gálvez P, Ta A, Perdrizet J. Expert Rev Pharmacoecon Outcomes Res. 2025
Real-world characteristics and outcomes of patients with multiple myeloma treated with belantamab mafodotin: a German claims data study. Luna J, d’Estrube T, Jacobsen A, Lehne M, Wellmann-Pichler B, Mevius A, Dornig S. Ann Hematol. 2025
Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study. Batyrbekova N, Hultcrantz M, Ravn Landtblom A, Szulkin R, Dickman PW, Andersson TM, Syriopoulou E. Br J Haematol. 2025
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Perez Cruz I, Hlavacek P. J Blood Med. 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK. J Clin Oncol. 2025
Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes. O’Donnell HK, Simmons KM, Gitelman SE, Dex T, Hill R, Wieloch M, Zaccai J, D’Souza J, Ginchereau Sowell F, Turnbull J, Hood KK. Diabetes Obes Metab. 2025
Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn’s Perianal Fistulas: A Systematic Literature Review. White I, Karki C, Geransar P, Leisle L, Junker S, Fleshner P. Inflamm Bowel Dis. 2025
Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. J Comp Eff Res. 2025
Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B. Adv Ther. 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study. Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C. Lung Cancer. 2025
Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies. Pavord ID, Brightling CE, Korn S, Martin NL, Ponnarambil SS, Molfino NA, Parnes JR, Ambrose CS. Pulm Ther. 2025
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges. Sarri G, Vinals L, Leisle L, Chau IC, Smalbrugge D, Lucassen K, Jemiai Y. J Comp Eff Res. 2025
A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the Netherlands. Smalbrugge D, Walsteijn T, de Feijter J, Suelmann B, Kearney M, Benedict A, Kapetanakis V, van Beekhuizen S. Oncol Ther. 2025
Combined Immediate-Release and Extended-Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation. Ahuja N, Kääriäinen S, Lovró Z, Lundblad M, Drott K, Lilienberg E, Engström MT, Saukkonen K, Scheinin M. Clin Pharmacol Drug Dev. 2025
Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study. Bolleddula J, Scheible H, Huber F, Seithel-Keuth A, Schieferstein H, Vagge DS, Mammasse N, Jaks E, Ferrer J, Moulin C, Dong J, Venkatakrishnan K, Papai Z. Clin Pharmacol Drug Dev. 2025
History, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross-sectional study. Cramer N, Kromer D, Bootsveld JM, Sennhenn-Kirchner S, Gerdes S, Sondermann W, Assaf K, Goebeler M, Wilsmann-Theis D, Günther C, Kromer C, Mössner R. J Dtsch Dermatol Ges. 2025
2025
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, Schepart A, Hughes DM, Hart J, Hlavacek P. Clinicoecon Outcomes Res. 2025
Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. J Comp Eff Res. 2025
Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study. Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, Chilelli A, Stoelzel M, Serikoff A, Spitzer SG. Adv Ther. 2025
A group concept mapping study of stakeholder perspectives on digital therapeutics economic value drivers. Sapanel Y, Cloutier LM, Tremblay G, Bourcet A, Koerber F, Lariviere D, Tadeo X, Ho D. NPJ Digit Med. 2025
PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis. Huerta JL, Ta A, Vinand E, Torres GI, Wannaadisai W, Huang L. Hum Vaccin Immunother. 2025
Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments. van Beekhuizen S, Che M, Monfort L, Hashim M, Azough A, Kubitz N, Griffin A, Price M. Pharmacoecon Open. 2025
Quantitative Bias Analysis for Single-Arm Trials With External Control Arms. Gupta A, Hsu G, Kent S, Duffield SJ, Merinopoulou E, Lockhart A, Arora P, Ray J, Wilkinson S, Scheuer N, Ramagopalan SV, Groenwold RHH, Popat S, Hernán MA. JAMA Netw Open. 2025
Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Azimpour K, Dorling P, Koulinska I, Kunduri S, Lan Z, Poritz J, Tremblay G, Raad-Faherty A. Adv Ther. 2025
Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis. Krieger J, Cox O, Flacke JP, Beilschmidt L, Mueller S, Maywald U, Koss MJ. Graefes Arch Clin Exp Ophthalmol. 2025
Conus medullaris termination: Assessing safety of spinal anesthesia in the L2-L3 interspace. Paul JE, Udovic LA, Oman K, Kim T, Bernstein L, Matteliano L, Singh N, Caldwell A, Vanniyasingam T, Thabane L. Acta Anaesthesiol Scand. 2025
Long-term risk of HCC in a DAA-treated national hepatitis C cohort, and a proposed risk score. Lybeck C, Bruce D, Szulkin R, Montgomery S, Aleman S, Duberg AS. Infect Dis (Lond). 2025
Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme. Çakar E, Ta A, Peters M, Vinand E, Waterval-Overbeek A, Ilic A, Perdrizet J. Infect Dis Ther. 2025
Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit. Perdrizet J, Ta A, Huang L, Wannaadisai W, Ilic A, Hayford K, Sabra A. Infect Dis Ther. 2025
Developing a prototype for federated analysis to enhance privacy and enable trustworthy access to COVID-19 research data. Eradat Oskoui S, Retford M, Forde E, Barnes R, J Hunter K, Wozencraft A, Thompson S, Orton C, Ford D, Heys S, Kennedy J, McNerney C, Peng J, Ghanbariadolat H, Rees S, H Mulholland R, Sheikh A, Burgner D, Brockway M, B Azad M, Rodriguez N, Zoega H, J Stock S, Calvert C, E Miller J, Fiorentino N, Racine A, Haggstrom J, Postlethwaite N. Int J Med Inform. 2025
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. Lurain K, Ramaswami R, Ekwede I, Eulo V, Goyal G, Menon M, Odeny TA, Sharon E, Wagner MJ, Wang CJ, Bhardwaj N, Friedlander PA, Abdul-Hay M, Cornejo Castro EM, Labo N, Marshall VA, Miley W, Moore K, Roshan R, Whitby D, Kask AS, Kaiser J, Han E, Wright A, Yarchoan R, Fling SP, Uldrick TS. J Clin Oncol. 2025
Influence of Treatment Effect Modifiers in Fabry Disease: A Systematic Literature Review. Azimpour K, Tordoff-Gibson C, Dorling P, Koulinska I, Kunduri S, Laliman-Khara V, Forsythe A. Adv Ther. 2025
Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes. O’Donnell HK, Simmons KM, Gitelman SE, Dex T, Hill R, Wieloch M, Zaccai J, D’Souza J, Ginchereau Sowell F, Turnbull J, Hood KK. Diabetes Obes Metab. 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Front Immunol. 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B. van Bömmel F, Verbinnen T, Agarwal K, Vanwolleghem T, Lampertico P, Buti M, Janczewska E, Bourliere M, Jezorwski J, Donohue K, Kim G, Kakuda TN, De Meyer S, Bakala A, Biermer M, Lenz O. Hepatol Commun. 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma. Ramaswami R, Kask AS, D’Amico L, Menon MP, Lurain K, Yarchoan R, Ekwede I, Couey P, Burnham E, Angeldekao A, Ha Lee B, Kaiser JC, Cheever M, Uldrick TS, Kwok LL, Wright A, Fling SP, Wang CJ. J Immunother Cancer. 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study. Fava M, Pani L, De Martin S, Cutler AJ, Gorodetzky CW, Vocci FJ, Sapienza FL, Kosten TR, Kröger C, Champasa P, Guidetti C, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi CE, Manfredi PL, Pappagallo M. J Clin Psychiatry. 2025
The effect of prenatal balanced energy and protein supplementation on gestational weight gain: An individual participant data meta-analysis in low- and middle-income countries. Wang D, Partap U, Liu E, Costa JC, Cliffer IR, Wang M, Nookala SK, Subramoney V, Briggs B, Ahmed I, Argaw A, Ariff S, Bhandari N, Chowdhury R, Erchick D, García-Guerra A, Ghaffarpour M, Hanley-Cook G, Huybregts L, Jehan F, Kaseb F, Krebs NF, Lachat C, Lama TP, Manandhar DS, McClure EM, Moore SE, Muhammad A, Neufeld LM, Prentice AM, Quezada-Sánchez AD, Roberfroid D, Saville NM, Shafiq Y, Shrestha BP, Sonko B, Soofi S, Taneja S, Tielsch JM, Toe LC, Valaei N, Fawzi WW. PLoS Med. 2025
Real-world experience with filgotinib for rheumatoid arthritis in Germany : A retrospective chart review. Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, De Leonardis F, Orzechowski HD, Gurrath M, Krüger K. Z Rheumatol. 2025
Testing One Primary and Two Secondary Endpoints in a Two-Stage Group Sequential Trial With Extensions. Tamhane AC, Xi D, Mehta CR, Romanenko A, Gou J. Stat Med. 202
Assessing the economic impact and healthcare resource utilization of inpatient pneumococcal disease among adults: a French national claims database study. Bailey MD, Farge G, Breau Brunel M, Mohanty S, Roy G, de Pouvourville G, de Wazieres B, Janssen C, Tauty S, Bugnard F, Goguillot M, Bénard S, Johnson KD. J Med Econ. 2025
Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey. O’Dwyer R, Junker S, Szulkin R, Kienzle S, Kearney M, Sridhar SS. Cancers (Basel). 2025
Recurrence of Cardiovascular Events After an Acute Myocardial Infarction in Patients with Multivessel Disease and Associated Healthcare Costs: A German Claims Data Analysis. Starry A, Picker N, Galduf J, Maywald U, Dittmar A, Spitzer SG. Pharmacoeconomics. 2025
2025
Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison. Anwer F, Lan T, Dolph M, Moradian H, Slaff S, Shih YH, Tang D. Future Oncol. 2025
Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population-based Study. Cherif H, Cai Q, Crivera C, Leon A, Rahman I, Leval A, Noel W, Kjellander C. Eur J Haematol. 2025
Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study. Whalen J, Chandra A, Kracker S, Ehl S, Seidel MG, Gulas I, Dron L, Velummailum R, Nagamuthu C, Liu S, Tutein Nolthenius J, Maccari ME. Clin Exp Immunol. 2025
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Sweis RF, Chatta GS, Jain RK, Moon H, Delacroix SE, Fang A, D’Amico L, Kask AS, Cheever MA, Fling S, Sharon E, Lacroix A, Kaiser JC, Pachynski RK, Yu EY. Clin Cancer Res. 2025
How much can we save by applying artificial intelligence in evidence synthesis? Results from a pragmatic review to quantify workload efficiencies and cost savings. Abogunrin S, Muir JM, Zerbini C, Sarri G. Front Pharmacol. 2025
Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces temperature-evoked pain in patients with peripheral neuropathic pain with sensory hypersensitivity, a randomized, double-blind, placebo-controlled, crossover study. Miclescu A, Karlsten R, Lönnstedt I, Halldin MM, Segerdahl M. Scand J Pain. 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials. Rekowski J, Guo C, Solovyeva O, Dimairo M, Rouhifard M, Patel D, Alger E, Ashby D, Berlin J, Boix O, Calvert M, Chan AW, Coschi CH, de Bono J, Evans TRJ, Garrett-Mayer E, Golub RM, Hayward KS, Hopewell S, Isaacs JD, Ivy SP, Jaki T, Kholmanskikh O, Kightley A, Lee S, Liu R, Maia I, Mander A, Marshall LV, Matcham J, Peck R, Rantell KR, Richards DP, Seymour L, Tanaka Y, Ursino M, Weir CJ, Yap C. EClinicalMedicine. 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols. Ursino M, Villacampa G, Rekowski J, Dimairo M, Solovyeva O, Ashby D, Berlin J, Boix O, Calvert M, Chan AW, Coschi CH, Evans TRJ, Garrett-Mayer E, Golub RM, Guo C, Hayward KS, Hopewell S, Isaacs JD, Ivy SP, Jaki T, Kholmanskikh O, Kightley A, Lee S, Liu R, Mander A, Marshall LV, Matcham J, Patel D, Peck R, Rantell KR, Richards DP, Rouhifard M, Seymour L, Tanaka Y, Weir CJ, de Bono J, Yap C. EClinicalMedicine. 2025
An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population. Fridh AC, Palmborg A, Ta A, Freigofaite D, Warren S, Perdrizet J. Hum Vaccin Immunother. 2024
Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis. O’Dwyer R, Musat MG, Gulas I, Hubscher E, Moradian H, Guenther S, Kearney M, Sridhar SS. Clin Genitourin Cancer. 2024
Comparing two transitioning strategies to paliperidone palmitate once-every-6-months. Correll CU, Johnston KL, Turkoz I, Kutch M, Knight RK, Doring M, Sajatovic M. CNS Spectr. 2024 Dec
Predictive and Interpretable Machine Learning of Economic Burden: The Role of Chronic Conditions Among Elderly Patients with Incident Primary Merkel Cell Carcinoma (MCC). Mbous YPV, Siddiqui ZA, Bharmal M, LeMasters T, Kolodney J, Kelley GA, Kamal KM, Sambamoorthi U. Clinicoecon Outcomes Res. 2024
TAZ downregulated ANXA1 expression to modulate myeloma cell interactions with bone marrow mesenchymal stromal cells. Abegunde SO, Grieve S, Reiman T. Exp Hematol. 2024
When does adjusting covariate under randomization help? A comparative study on current practices. Gao Y, Liu Y, Matsouaka R. BMC Med Res Methodol. 2024
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial. Rezelj VV, Paddenburg F, Diegbe ME, Nangosyah J, Reisinger EC, Hu W, Truyers C, Scheper G, Le Gars M, Hendriks J, Struyf F, Douoguih M, Schuitemaker H, Ruiz-Guiñazú J. Vaccines (Basel). 2024
Establishing the minimal clinically important difference of the Brief Fatigue Inventory for brain or CNS cancer patients undergoing radiotherapy. Gunn HJ, Zaniletti I, Breen WG, Leavitt T, Bogan A, Mahajan A, Brown PD, Yan E, Vora SA, Merrell KW, Ashman JB, Peterson JL, Leenstra JL, Wilson ZC, Laughlin BS, Laack NN, DeWees TA. Neurooncol Pract. 2024
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial. Ruiz Seco MP, Paño Pardo JR, Schoergenhofer C, Dings C, Lehr T, Herth F, Krendyukov A, Straub C, Kappler M, Jilma B, Fricke H, Pardo J, de Miguel D, Thiemann M, Bergmann M, Walczak H, Hoeger T. EClinicalMedicine. 2024
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T; SENOMAC Trialists’ Group. Lancet Oncol. 2024
Histopathology underlying environmental enteric dysfunction in a cohort study of undernourished children in Bangladesh, Pakistan, and Zambia compared with United States children. Kelly P, VanBuskirk K, Coomes D, Mouksassi S, Smith G, Jamil Z, Hossain MS, Syed S, Marie C, Tarr PI, Sullivan PB, Petri WA Jr, Denno DM, Ahmed T, Mahfuz M, Ali SA, Moore SR, Ndao IM, Tearney GJ, Ömer H Yilmaz, Raghavan SS, Moskaluk CA, Liu TC; EEDBI Consortium. Am J Clin Nutr. 2024
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models. Freitag A, Sarri G, Ta A, Gurskyte L, Cherepanov D, Hernandez LG. Pharmacoeconomics. 2024
Anthropometry relationship with duodenal histologic features of children with environmental enteric dysfunction: a multicenter cross-sectional study. Jamil Z, VanBuskirk K, Mweetwa M, Mouksassi S, Smith G, Ahmed T, Chandwe K, Denno DM, Fahim SM, Kelly P, Mahfuz M, Mallawaarachchi I, Marie C, Moore SR, Petri WA Jr, Ali SA; EEDBI Consortium. Am J Clin Nutr. 2024
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies. Sarri G, Hernandez LG. J Comp Eff Res. 2024
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia. Sutton AJ, Lupu DS, Bergin SP, Holland TL, McAdams SA, Dadwal SS, Nguyen K, Nolte FS, Tremblay G, Perkins BA. Pharmacoeconomics. 2024
Long-term risk of HCC in a DAA-treated national hepatitis C cohort, and a proposed risk score. Lybeck C, Bruce D, Szulkin R, Montgomery S, Aleman S, Duberg AS. Infect Dis (Lond).
EN 
FR 
